Oct 27 (Reuters) - Teva Pharmaceuticals has agreed to pay $35 million and withdraw six patents from a U.S. regulatory list to settle claims that the drugmaker delayed generic competition for its QVAR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback